{"id":"NCT00171704","sponsor":"Novartis Pharmaceuticals","briefTitle":"A Study to Evaluate the Effect of Letrozole and Tamoxifen on Bone and Lipids in Postmenopausal Women With Breast Cancer","officialTitle":"A Study to Evaluate the Effect of Letrozole and Tamoxifen on Bone and Lipids in Postmenopausal Women With Breast Cancer","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2005-04","primaryCompletion":"2011-03","completion":"2011-03","firstPosted":"2005-09-15","resultsPosted":"2012-06-04","lastUpdate":"2017-03-03"},"enrollment":263,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Hormone Sensitive Resected Primary Breast Cancer in Postmenopausal Women"],"interventions":[{"type":"DRUG","name":"Letrozole","otherNames":[]},{"type":"DRUG","name":"Tamoxifen","otherNames":[]}],"arms":[{"label":"Letrozole","type":"EXPERIMENTAL"},{"label":"Tam-Let","type":"EXPERIMENTAL"}],"summary":"Estrogen is known to be a regulator of bone and lipid metabolism. Letrozole is a potent inhibitor of estrogen synthesis.\n\nThis study evaluated the effects of letrozole and tamoxifen on bone and lipid metabolism in postmenopausal women with resected, receptor positive early breast cancer.","primaryOutcome":{"measure":"Percent Change From Baseline of Bone Mineral Density of the Lumbar Spine (L2-l4)","timeFrame":"Baseline, 24 months","effectByArm":[{"arm":"Letrozole","deltaMin":-4.63,"sd":null},{"arm":"Tam-Let","deltaMin":0.37,"sd":null}],"pValues":[]},"eligibility":{"minAge":"50 Years","sex":"FEMALE","healthyVolunteers":false,"inclusionCount":11,"exclusionCount":15},"locations":{"siteCount":13,"countries":["Denmark","United Kingdom"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":50,"n":133},"commonTop":["Arthralgia","Hypercholesterolaemia","Hypertension","Back pain","Oedema peripheral"]}}